StreetAlpha
13F holdings · Q3 2026

B Group

Dallas, TX · files as B Group, Inc.
Know the moment B Group filesYou follow B Group An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 2043476

B Group reported 19 stocks worth $162M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ADMA (20.2%), FTH (11.2%) and PALI (9.5%). Compared with Q2 2026, the fund opened new positions in QTTB, added to NRXP, GPCR and DRUG and trimmed IOVA, SYRE and ORKA.

Latest filing: what B Group did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
1 new3 added3 trimmed0 sold outBought about $3.7M · sold about $18.3M
New 1
Added 3
Trimmed 3
Sold out 0

None

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$162M−8.0% vs last quarter
Stocks held191 new · 0 sold out
Top 5 weight55.9%fairly concentrated
Turnover14%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
ADMA
Adma Biologics Inc
$32.7M20.2%3.3MNo change8 of 8
2
FTH
Sensei Biotherapeutics Inc
$18.1M11.2%610KNo change2 of 8
3
PALI
Palisade Bio Inc
$15.4M9.5%11.4MNo change4 of 8
4
NRXP
Nrx Pharmaceuticals Inc
$12.5M7.7%4.3M+185K (+5%)3 of 8
5
ZLAB
Zai Lab Ltd
$11.9M7.3%451KNo change8 of 8
6
PRAX
Praxis Precision Medicines I
$9.7M6.0%33KNo change7 of 8
7
SGHT
Sight Sciences Inc
$9.1M5.6%970KNo change8 of 8
8
TSHA
Taysha Gene Therapies Inc
$8.8M5.4%1.8MNo change8 of 8
9
IOVA
Iovance Biotherapeutics Inc
$6.3M3.9%425K−1.1M (−72%)8 of 8
10
GPCR
Structure Therapeutics Inc
$5.6M3.5%180K+40K (+29%)4 of 8
🔒 9 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Reported value

last 8 quarters
$164MQ4 '24
$115MQ1 '25
$116MQ2 '25
$105MQ3 '25
$135MQ4 '25
$135MQ1 '26
$176MQ2 '26
$162MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

B Group 13F FAQ

What does B Group own?

B Group reported 19 stocks worth $162M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ADMA (20.2%), FTH (11.2%) and PALI (9.5%). The table above lists every position in the filing (the top 10 without an account).

What did B Group buy and sell in Q3 2026?

Compared with Q2 2026: 1 new positions, 3 added to, 3 trimmed and 0 sold out. New positions include QTTB.

When will B Group file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is B Group's portfolio worth?

The Q3 2026 filing reports $162M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.